The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Comparing efficacy outcomes of ide-cel versus conventional care in R/R myeloma
Nina Shah, MD, University of California-San Francisco, San Francisco, CA, discusses an analysis that compared efficacy outcomes seen in the MAMMOTH study, a retrospective observational study of conventional care regimens, and the KarMMA trial (NCT03361748) of the BCMA-targeted CAR-T cell therapy idecabtagene vicleucel (ide-cel), both in triple-class refractory multiple myeloma patients. The analysis used matching-adjusted indirect comparisons to assess the efficacy of ide-cel and conventional care. The results showed that, in a matched population, ide-cel treatment was associated with a significantly higher overall response rate (ORR) than conventional care. Progression free survival and overall survival were also higher in the ide-cel cohort. When looking in isolation at conventional care patients who received targeted therapies, the superiority of ide-cel still remained. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding: Celgene/BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar
Advisory role: GSK, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx, Kite, Karyopharm
